SANA BIOTECHNOLOGY INC (SANA) Stock News

USA - NASDAQ:SANA - US7995661045 - Common Stock

3.25 USD

+0.16 (+5.18%)

Last: 9/22/2025, 9:04:45 PM

3.27 USD

+0.02 (+0.62%)

After Hours: 9/22/2025, 9:04:45 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SANA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Sana Biotechnology, Inc

Sana Biotechnology to Present at September 2025 Investor Conferences

a month ago - By: Sana Biotechnology, Inc

Sana Biotechnology to Present at September 2025 Investor Conferences

a month ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares

a month ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares

3 months ago - By: Benzinga - Mentions: LCTX

Two Biotech Stocks Poised For Big Moves On Monday

a month ago - By: Sana Biotechnology, Inc

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

a month ago - By: Sana Biotechnology, Inc

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

2 months ago - By: Benzinga - Mentions: SABR JMIA AVAH RDW ...

Dow Dips Over 300 Points; US Initial Claims Rise

2 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Pricing of Public Offering

2 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Pricing of Public Offering

2 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

2 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

2 months ago - By: Yahoo Finance

Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects

2 months ago - By: Yahoo Finance - Mentions: MS

Citi Remains Bullish on Sana Biotechnology (SANA)

2 months ago - By: Yahoo Finance

Citi Maintained a Buy Rating on Sana Biotechnology (SANA)

2 months ago - By: Yahoo Finance - Mentions: MS

Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley

3 months ago - By: Yahoo Finance - Mentions: GS

Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results

3 months ago - By: Yahoo Finance - Mentions: BAC RLAY

BofA Remains Bullish on Sana Biotechnology (SANA)

3 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

3 months ago - By: Sana Biotechnology, Inc

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression